Immunome Inc.
Immunome Inc. (IMNM): 10 pipeline candidates · 1 upcoming catalyst · ~30 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
30.0 months
D/E 0.05 · 0% dilution
Lead: Approved
10 candidates
1 upcoming, next in ~166d
5 buys · 7 sells (180d)
A transparent, data-derived signal for Immunome Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.0B
Cash
$582.9M
Quarterly Burn
$58.6M
Runway
30.0 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| 177lu-im-3050 | Early Phase 1 |
| al102 | Phase 2/Phase 3 |
| IM-1021 | Phase 1 |
| im-1335 | Preclinical |
| im-1340 | Phase 1 |
| im-1617 | Phase 1 |
| im-3050 | Phase 1 |
| moxifloxacin | Phase 1 |
| trodelvy | Approved |
| varegacestat | Phase 1 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
198
Total value held
$2.19B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 16,969,954 | $371.1M |
| vanguard capital management llc | 8,859,394 | $193.8M |
| blackrock, inc. | 8,168,674 | $178.6M |
| state street corp | 5,399,901 | $118.1M |
| primecap management co/ca/ | 4,788,231 | $104.7M |
| wellington management group llp | 4,731,977 | $103.5M |
| driehaus capital management llc | 4,099,901 | $89.7M |
| enavate sciences gp, llc | 3,613,799 | $79.0M |
| woodline partners lp | 3,150,796 | $68.9M |
| morgan stanley | 2,841,589 | $62.1M |
Showing top 10 of 198 institutional holders of Immunome Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Immunome Inc.'s pipeline?
Immunome Inc. (IMNM) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Immunome Inc.'s lead drug candidate?
Immunome Inc.'s most advanced tracked candidate is 177lu-im-3050 (Early Phase 1) for Solid Malignancies.
What is Immunome Inc.'s next catalyst?
Immunome Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing " — expected December 1, 2026.
What is Immunome Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Immunome Inc. has approximately 30.0 months of cash runway.
What is Immunome Inc.'s market capitalization?
Immunome Inc.'s market capitalization is approximately $2.0B.
Get the full picture on Immunome Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.